Eye blood flow changes linked to MS: what it means

Credibility

Interest

Key Takeaway

Eyes of people with MS often show lower tiny blood vessel density on OCT-A scans, which may reflect nerve damage and help track disease effects.

What They Found

Researchers looked at 18 studies using a special eye scan called OCT-A that pictures tiny blood vessels in the retina (the back of the eye) and the optic nerve (the nerve that connects eye to brain). They found that people with MS had lower vessel density in several eye layers, meaning fewer or thinner tiny blood vessels compared to healthy people. Eyes that had a past optic neuritis attack (sudden inflammation of the optic nerve that can happen in MS) tended to show bigger drops in vessel density than eyes without that history. Different scan machines showed similar patterns, so the finding was not limited to just one device. Overall, the eye areas called the superficial capillary plexus, deep capillary plexus, and radial peripapillary capillaries showed the most consistent decreases in vessel density in MS patients.

Who Should Care and Why

People with MS and their caregivers should care because the eye scans used in this study might give clues about brain and nerve health without needing brain scans. Think of the eye like a window to the brain — changes in its tiny blood vessels can hint at nerve damage or inflammation. Eye doctors and MS neurologists might use OCT-A as an extra tool to monitor disease over time, much like checking the tire pressure to know if a car needs attention. Patients who had optic neuritis may get extra benefit from these scans since their eyes showed clearer changes. Caregivers can use this information to ask doctors about eye imaging if they notice vision changes or want another way to follow MS progression.

Important Considerations

Not all studies were identical: they used different machines, software, and patient groups, so results vary a bit between studies. A lower vessel density on OCT-A does not by itself prove worsening MS — it is a clue that needs to be combined with symptoms and other tests. More research is needed to know how well OCT-A predicts future vision or overall MS progression before it becomes a standard test for every patient.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Early Research Clinical Trials

Article Topics:

MSMeta-analysisMultiple sclerosisOCTOCT-AOptical coherence tomographyOptical coherence tomography angiographyPerfusion densityRetinaVascular density

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News